The speciality pharma will gain the approved Danyelza and a radiopharma pipeline.
ApexOnco Front Page
Recent articles
A phase 2 trial of the Car-T project BNT211 is withdrawn just months after it began.
Abstract titles reveal some of ASCO’s key datasets.
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.